Table 2

Efficacy data from the phase III trial

Efficacy variableRandomized and treated patients
Fully supplemented patients
Pemetrexed + cisplatin (n = 226)Cisplatin (n = 222)Pemetrexed + cisplatin (n = 168)Cisplatin (n = 163)
Median overall survival, mo (95% confidence interval)12.1 (10.0-14.4)9.3 (7.8-10.7)13.3 (11.4-14.9)10.0 (8.4-11.9)
Hazard ratio (95% confidence interval)0.77 (0.61-0.96)0.76 (0.57-1.0)
P (log-rank)*0.0210.051
% Alive35.828.443.536.8
  • * P is based on the two-sided log-rank test.